Apex Research Reference
Sermorelin
Sermorelin Acetate — GHRH(1-29) Analog
GHRH ANALOG GH SECRETAGOGUE ANTI-AGING PITUITARY NIGHTLY PROTOCOL
01 — Identity

What Is Sermorelin?

1982
CHARACTERIZED
GHRH 1-29
SEQUENCE
Pituitary
TARGET ORGAN
~12 min
HALF-LIFE
Origin
Synthetic analog of the first 29 amino acids of endogenous GHRH. FDA approved 1997 as Geref for pediatric GH deficiency. Withdrawn from market 2008 for business reasons — not safety.
Chemical Class
29-amino acid peptide. Linear. Acetate salt form. Synthetic analog of endogenous GHRH(1-44).
Primary Use
Stimulates the pituitary to produce and secrete its own growth hormone. Maintains natural pulsatile GH release. Anti-aging, body composition, sleep quality, recovery.
Administration
Subcutaneous injection. Nightly before bed — FASTED. Pituitary stimulation synchronized with natural GH pulse during slow-wave sleep.
Key distinction: Sermorelin stimulates YOUR pituitary to make GH — it does not inject exogenous growth hormone. This preserves the natural pulsatile GH release pattern and does not suppress the pituitary axis. It's a fundamentally safer approach than direct HGH injection for long-term use.
02 — Research History

Discovery & Research Timeline

1960s–1970s
GHRH (Growth Hormone Releasing Hormone) is hypothesized based on hypothalamic regulation studies. Scientists identify that the hypothalamus controls pituitary GH secretion via a releasing factor.
1982
Human GHRH is isolated and sequenced. Multiple groups including Guillemin (Salk Institute) and Vale (Salk) characterize the full 44-amino acid sequence. Sermorelin — the bioactive 1-29 fragment — is identified as retaining full GH-stimulating potency.
1990s
Sermorelin (Geref) enters clinical development for pediatric growth hormone deficiency. Shown to increase GH secretion, IGF-1 levels, and linear growth in GH-deficient children with excellent safety profile.
1997
FDA approves Sermorelin acetate (Geref) for treatment of growth hormone deficiency in children. Becomes the first GHRH analog approved for clinical use in the United States.
2008
Geref withdrawn from commercial market by Serono — a business decision, not a safety withdrawal. Compounded Sermorelin continues in anti-aging and wellness medicine as GH optimization tool in adults.
2010–Present
Sermorelin becomes foundational to functional medicine GH optimization protocols. Widely compounded and used alongside GHRP agents (Ipamorelin) for synergistic GH pulse amplification. Foundation for all subsequent GHRH analogs (CJC-1295, Tesamorelin).
03 — Primary Benefits

Documented Effects

01
Pituitary GH Stimulation
Directly activates GHRH receptors on pituitary somatotrophs, triggering natural pulsatile GH secretion. Maintains the body's own GH rhythm rather than imposing an artificial exogenous pattern.
02
Body Composition
GH-driven IGF-1 increase promotes lipolysis (fat mobilization) and lean muscle preservation. Consistent 3–6 month cycles show measurable reductions in body fat percentage and improvements in lean mass.
03
Sleep Architecture Enhancement
GH pulses naturally peak during slow-wave (deep) sleep. Sermorelin amplifies the nightly GH pulse, improving slow-wave sleep duration and quality — users commonly report deeper, more restorative sleep within weeks.
04
Tissue Recovery
Elevated GH and downstream IGF-1 accelerate repair of muscle, tendon, and connective tissue. Recovery between training sessions improves with 4–8 weeks of consistent use.
05
Skin & Collagen
IGF-1 upregulates collagen synthesis in fibroblasts. Users report improvements in skin elasticity, reduced fine lines, and improved skin texture with sustained cycles.
06
Bone Density Support
GH/IGF-1 axis stimulates osteoblast activity. Long-term Sermorelin use associated with improved bone mineral density — relevant for aging populations at osteopenia risk.
07
Cognitive Clarity
GH receptors exist throughout the brain, including hippocampus and prefrontal cortex. Users commonly report improved mental sharpness, focus, and mood — particularly after 4–8 weeks of consistent nightly use.
04 — Reconstitution

Mixing & Storage

▸ Standard Reconstitution — 10mg Vial
10mg vial + 300 units BAC water = 33.3 mcg per unit on insulin syringe
10,000 mcg total per vial · Refrigerate after reconstitution · Use within 4–6 weeks · Protect from light
Add BAC water slowly by directing the stream down the side of the vial — do not inject directly onto the powder. Swirl gently; do not shake. Solution should be clear and colorless. Discard if cloudy or particulate matter present.
UNRECONSTITUTED
Refrigerate at 2–8°C. Stable for shipping at room temperature short-term. Do not freeze lyophilized powder.
RECONSTITUTED
Refrigerate at 2–8°C. Use within 4–6 weeks. Keep away from light. Do not freeze liquid solution.
05 — Dosing Protocol

Dose Levels & Unit Draws

LevelDoseSyringe DrawDescription
LOW
100mcg
3 units on insulin syringe		 3u Conservative anti-aging starting dose. Good for first-time users or those with GH sensitivity concerns. Nightly before bed, fasted.
STANDARD
200–300mcg
6–9 units on insulin syringe		 6–9u Standard therapeutic range for GH optimization. Most clinical protocols and anti-aging practitioners use 200–300mcg nightly. Best balance of efficacy and tolerability.
HIGH
500mcg
15 units on insulin syringe		 15u Upper range. Diminishing returns above 500mcg due to receptor saturation at the pituitary. Higher doses do not proportionally increase GH output.
⚠ NIGHTLY FASTED ONLY. Sermorelin must be taken on an empty stomach — no food for 2–3 hours before injection. Insulin from recent meals directly blunts GH release at the pituitary level. This is the most critical timing rule for all GHRH analogs.
06 — Timing & Frequency

When & How Often

VariableRecommendationWhy
Primary Timing Nightly — 30–60 min before sleep GH naturally pulses 60–90 minutes after sleep onset during slow-wave sleep. Sermorelin amplifies this natural pulse by priming the pituitary at sleep onset.
Fed State FASTED — 2–3 hrs no food Insulin is the primary inhibitor of GH release. Eating raises insulin, which directly suppresses the GH pulse Sermorelin is trying to amplify. No food after dinner if dosing at bedtime.
Frequency Daily or 5 days on / 2 off Daily nightly use is standard. Some practitioners use 5 days on / 2 days off (weekends off) to reduce receptor desensitization risk, though evidence for this in Sermorelin is limited.
Stack Timing Combine with Ipamorelin Sermorelin (GHRH) + Ipamorelin (GHRP) in the same nightly injection produces 2–3× the GH pulse of either alone. Synergistic — two different receptor pathways amplifying the same output.
07 — Biomarker Monitoring

Lab Tests & Optimal Ranges

▸ GH Axis Efficacy
BiomarkerLab TestClinical RangeOptimal Range
IGF-1
Primary GH output marker		 Serum IGF-1 CLINICALAge-dependent OPTIMALUpper third of age range
IGFBP-3
GH/IGF-1 binding protein		 Serum IGFBP-3 CLINICALAge-dependent OPTIMALUpper third of age range
GH (spot, AM fasting) Serum GH CLINICAL0–10 ng/mL OPTIMALTrending upward from baseline
▸ Metabolic Safety Monitoring
BiomarkerLab TestClinical RangeOptimal Range
Fasting Glucose Fasting plasma glucose CLINICAL70–100 mg/dL OPTIMAL75–90 mg/dL
Fasting Insulin Serum fasting insulin CLINICAL2–25 µIU/mL OPTIMAL2–6 µIU/mL
HbA1c Hemoglobin A1c CLINICAL<5.7% OPTIMAL4.6–5.3%
AST / ALT CMP CLINICALAST 10–40 / ALT 7–56 U/L OPTIMALAST <26 / ALT <26 U/L
CBC Complete Blood Count CLINICALStandard ranges OPTIMALMid-range; WBC 4.5–6.0
⚠ Sermorelin was FDA-approved as Geref but is no longer commercially available. Compounded Sermorelin is used for wellness/anti-aging under physician supervision. GH axis optimization warrants monitoring of glucose metabolism — elevated GH can reduce insulin sensitivity. Do not use in active malignancy. Thyroid function should be assessed before starting GH optimization protocols as hypothyroidism blunts GH response.
08 — Cycle Protocol

Cycle Length, Frequency & Timing

STANDARD CYCLE
3–6 Months
Nightly at 200–300mcg. IGF-1 typically rises measurably at 8 weeks, with full body composition effect at 3–6 months. Most practitioners run 6-month cycles.
BREAK
1–2 Months
Allow the pituitary to reset after sustained stimulation. Some practitioners prefer 5 days on / 2 days off within cycles to reduce desensitization risk.
PROTOCOL SUMMARY
3–6 mo
CYCLE LENGTH
Nightly
FREQUENCY
PM
TIMING
Fasted
FED STATE
1–2 mo
BREAK
SC
ROUTE